Related Experiment Videos
Early-onset myasthenia gravis
Insights
Myasthenia gravis in children presents in two forms: neonatal and juvenile. Juvenile onset myasthenia gravis, an autoimmune disorder, may be more common in young children than previously thought.
Area of Science:
- Neurology
- Pediatrics
- Immunology
Background:
- Myasthenia gravis (MG) is a neuromuscular disorder affecting neuromuscular transmission.
- Distinguishing between autoimmune and congenital forms of MG is crucial for patient management.
Observation:
- This study reviewed 11 children with myasthenia gravis symptoms by age 3.
- Six patients had persistent neonatal myasthenia gravis (a non-immunological familial disorder).
- Five patients had juvenile onset myasthenia gravis (an autoimmune disorder).
Findings:
- Juvenile onset myasthenia gravis, previously thought rare in early childhood, was observed in 5 of 11 young patients.
- The availability of anti-acetylcholine receptor antibody assays aids in differentiating autoimmune MG from congenital forms.
- Autoimmune myasthenia gravis may be underdiagnosed in children under 3 years old.
Implications:
- Early and accurate diagnosis of myasthenia gravis subtypes is vital.
- Distinguishing between autoimmune and congenital MG impacts treatment strategies and prognosis.
- Increased awareness of juvenile onset myasthenia gravis in young children is warranted.
Abstract:
Signs of myasthenia gravis developed by age 3 years in 11 children. Six of these patients had persistent neonatal myasthenia gravis, a familial abnormality of neuromuscular transmission that is not immunologically mediated. Five patients had juvenile onset myasthenia gravis, an autoimmune disorder similar to myasthenia gravis in adults. Autoimmune myasthenia has rarely been recognized by age 3 years, but the presence of five cases in our series suggests that the disorder may be more common in young children than once believed. The development of anti-acetylcholine receptor antibody assays makes it easier to distinguish autoimmune myasthenia gravis from the congenital forms. This distinction is important, because the prognosis, treatment, and risk of recurrence in family members is different for each type of myasthenia.